Johnson & Johnson (NYSE:JNJ) Shares Bought by DDD Partners LLC

DDD Partners LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 50.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 145,274 shares of the company's stock after acquiring an additional 48,774 shares during the period. Johnson & Johnson accounts for approximately 2.9% of DDD Partners LLC's investment portfolio, making the stock its 8th biggest position. DDD Partners LLC's holdings in Johnson & Johnson were worth $24,092,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Hudson Value Partners LLC grew its position in shares of Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after buying an additional 1,022 shares during the last quarter. Proficio Capital Partners LLC grew its position in shares of Johnson & Johnson by 22.0% in the 4th quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company's stock valued at $2,885,000 after buying an additional 3,594 shares during the last quarter. Horizon Investments LLC grew its position in shares of Johnson & Johnson by 10.1% in the 4th quarter. Horizon Investments LLC now owns 25,627 shares of the company's stock valued at $3,706,000 after buying an additional 2,361 shares during the last quarter. Finally, Brooklyn FI LLC grew its position in shares of Johnson & Johnson by 6,239.7% in the 4th quarter. Brooklyn FI LLC now owns 127,682 shares of the company's stock valued at $19,795,000 after buying an additional 125,668 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE JNJ traded up $0.67 on Friday, reaching $163.65. The company's stock had a trading volume of 9,764,459 shares, compared to its average volume of 8,138,165. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The stock has a market cap of $393.75 billion, a PE ratio of 17.50, a PEG ratio of 2.18 and a beta of 0.41. The firm's 50 day moving average is $154.29 and its two-hundred day moving average is $154.97.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the firm earned $2.82 earnings per share. The business's quarterly revenue was up 5.8% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on JNJ. Guggenheim raised their price objective on shares of Johnson & Johnson from $164.00 to $167.00 and gave the company a "neutral" rating in a research note on Thursday. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. UBS Group restated a "buy" rating and set a $190.00 target price (up previously from $180.00) on shares of Johnson & Johnson in a research report on Thursday. Raymond James Financial cut their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Finally, Bank of America lifted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $172.87.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.